Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) EBT (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed EBT for 12 consecutive years, with -$4.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 13.81% year-over-year to -$4.2 million, compared with a TTM value of -$19.2 million through Sep 2025, up 10.84%, and an annual FY2024 reading of -$20.8 million, up 10.3% over the prior year.
  • EBT was -$4.2 million for Q3 2025 at Lisata Therapeutics, up from -$4.7 million in the prior quarter.
  • Across five years, EBT topped out at -$4.2 million in Q3 2025 and bottomed at -$6.4 million in Q2 2023.
  • Average EBT over 3 years is -$5.3 million, with a median of -$5.3 million recorded in 2023.
  • Peak annual rise in EBT hit 20.65% in 2024, while the deepest fall reached 0.19% in 2024.
  • Year by year, EBT stood at -$5.4 million in 2023, then grew by 14.07% to -$4.6 million in 2024, then increased by 7.83% to -$4.2 million in 2025.
  • Business Quant data shows EBT for LSTA at -$4.2 million in Q3 2025, -$4.7 million in Q2 2025, and -$5.7 million in Q1 2025.